UQ Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia.
Cancer and Ageing Research Program, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
Stem Cells Transl Med. 2022 Apr 29;11(4):372-382. doi: 10.1093/stcltm/szac005.
Fetal growth restriction (FGR) occurs when a fetus is unable to grow normally due to inadequate nutrient and oxygen supply from the placenta. Children born with FGR are at high risk of lifelong adverse neurodevelopmental outcomes, such as cerebral palsy, behavioral issues, and learning and attention difficulties. Unfortunately, there is no treatment to protect the FGR newborn from these adverse neurological outcomes. Chronic inflammation and vascular disruption are prevalent in the brains of FGR neonates and therefore targeted treatments may be key to neuroprotection. Tissue repair and regeneration via stem cell therapies have emerged as a potential clinical intervention for FGR babies at risk for neurological impairment and long-term disability. This review discusses the advancement of research into stem cell therapy for treating neurological diseases and how this may be extended for use in the FGR newborn. Leading preclinical studies using stem cell therapies in FGR animal models will be highlighted and the near-term steps that need to be taken for the development of future clinical trials.
胎儿生长受限(FGR)是指由于胎盘无法向胎儿提供充足的营养和氧气,导致胎儿无法正常生长。患有 FGR 的儿童有很高的风险出现终身不良神经发育结局,如脑瘫、行为问题以及学习和注意力困难。不幸的是,目前尚无治疗方法可以保护 FGR 新生儿免受这些不良神经结局的影响。慢性炎症和血管破坏在 FGR 新生儿的大脑中很常见,因此靶向治疗可能是神经保护的关键。通过干细胞疗法进行组织修复和再生已成为治疗有神经损伤和长期残疾风险的 FGR 婴儿的一种潜在临床干预措施。本综述讨论了干细胞疗法治疗神经疾病的研究进展,以及如何将其扩展用于 FGR 新生儿。将重点介绍使用干细胞疗法治疗 FGR 动物模型的主要临床前研究,以及为开展未来临床试验需要采取的近期步骤。